ArticleNPJ Parkinson's disease2023
Two-year clinical progression in focal and diffuse subtypes of Parkinson's disease.
Article in NPJ Parkinson's disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Disease-Duration-Specific Percentiles for Prospective Subtyping of Parkinson's Disease: A PPMI-Based Study.Movement disorders clinical practice · 2026Article
- Comparative analysis of progression milestones across Parkinson's disease clinical, pathological, and data-driven subtypes: a 10-year follow-up.NPJ Parkinson's disease · 2026Article
- Physical frailty, depressive symptoms, and cognitive decline before and after Parkinson's disease diagnosis: a population-based prospective study of the SHARE and ELSA cohorts.NPJ Parkinson's disease · 2026Article
- Faster reaction times of CSF alpha-synuclein seed amplification assay predict the diffuse malignant subtype of Parkinson's disease at 10-year follow-up.Journal of Parkinson's disease · 2026Article
- Parkinson's disease progression is shaped by longitudinal changes in cerebral compensation.Brain : a journal of neurology · 2026Article
- Understanding individual neurodegenerative progression in Parkinson's disease through normative modelling.Scientific reports · 2025Article
- Faster reaction times of CSF Alpha-Synuclein Seed Amplification Assay predict the Diffuse Malignant subtype of Parkinson's Disease at 10-year follow-up.medRxiv : the preprint server for health sciences · 2025Article
- DualGCN-GE: integration of spatiotemporal representations from whole-blood expression data with dual-view graph convolution network to identify Parkinson's disease subtypes.BMC bioinformatics · 2025Article
- Impact of Harmonization on MRI Radiomics Feature Variability Across Preprocessing Methods for Parkinson's Disease Motor Subtype Classification.Journal of imaging informatics in medicine · 2025Article
- Identification of a circRNA-miRNA-mRNA interactome associated with Parkinson's disease progression.Journal of Parkinson's disease · 2025Article
- Four questions to predict cognitive decline in de novo Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Exploring glymphatic system alterations in iRBD and Parkinson's disease using automated DTI-ALPS analysis.NPJ Parkinson's disease · 2025Article
- Plasma GFAP and NfL associate with cerebral glucose metabolism in putative brain-first and body-first Parkinson's disease subtypes.NPJ Parkinson's disease · 2025Article
- History of Traumatic Brain Injury Does Not Influence Rate of Progression of Clinical or Pathological Outcomes in Two Early Parkinson's Disease Cohorts.European journal of neurology · 2025Observational
- Changes in Action Tremor in Parkinson's Disease over Time: Clinical and Neuroimaging Correlates.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Recursive seed amplification detects distinct α-synuclein strains in cerebrospinal fluid of patients with Parkinson's disease.Acta neuropathologica communications · 2025Article
- The added value of anosmic subtype on motor subtype in Parkinson's disease: a pilot study.Scientific reports · 2025Article
- Non-motor asymmetry and dopamine degeneration in Parkinson's disease.Brain communications · 2025Article
- Normative trajectories of RImaging neuroscience (Cambridge, Mass.) · 2025Article
- Hot Topics and Frontiers of Resting-State fMRI in Parkinson's Disease: Research Trends and Paradigm Shifts From a Bibliometric Perspective.Parkinson's disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Heterogeneity in Parkinson's disease (PD) presents a barrier to understanding disease mechanisms and developing new treatments. This challenge may be partially overcome by stratifying patients into clinically meaningful subtypes. A recent subtyping scheme classifies de novo PD patients into three subtypes: mild-motor predominant, intermediate, or diffuse-malignant, based on motor impairment, cognitive function, rapid eye movement sleep behavior disorder (RBD) symptoms, and autonomic symptoms. We aimed to validate this approach in a large longitudinal cohort of early-to-moderate PD (n = 499) by assessing the influence of subtyping on clinical characteristics at baseline and on two-year progression. Compared to mild-motor predominant patients (42%), diffuse-malignant patients (12%) showed involvement of more clinical domains, more diffuse hypokinetic-rigid motor symptoms (decreased lateralization and hand/foot focality), and faster two-year progression. These findings extend the classification of diffuse-malignant and mild-motor predominant subtypes to early-to-moderate PD and suggest that different pathophysiological mechanisms (focal versus diffuse cerebral propagation) may underlie distinct subtype classifications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.